DNMT3A and acute lymphoblastic leukemia: Principle component analysis of the control DMSO-treated cells to compare the global transcriptomes of the patient cells at baseline identified 2 DNMT3A-wild-type T-ALL samples that clustered with the DNMT3A-mutant samples (Figure 6C), which we designated “DNMT3A-mutant–like.” Western blot analysis showed patients with DNMT3A-mutant–like disease also had very low expression of DNMT3A, similar to patients with genetic mutations in DNMT3A (Figure 6D).